Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency well-characterized in hematologic malignancies but considered rare in solid tumors. In breast cancer, TLS has been documented only in sporadic case reports, and the evolving treatment landscape—including CDK4/6 inhibitors, PI3K inhibitors, novel endocrine agents, and antibody-drug conjugates—may introduce previously unrecognized TLS risks.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
